Shares of Haemonetics Corporation (NYSE:HAE – Get Free Report) have received a consensus rating of “Moderate Buy” from the eleven brokerages that are presently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $90.8889.
A number of research analysts have recently weighed in on HAE shares. Wall Street Zen raised shares of Haemonetics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Barrington Research set a $95.00 price objective on Haemonetics in a research note on Friday, August 7th. Mizuho increased their target price on shares of Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. BTIG Research lifted their price objective on shares of Haemonetics from $84.00 to $96.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings upgraded Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th.
Check Out Our Latest Stock Analysis on HAE
Haemonetics Trading Down 0.9%
Haemonetics (NYSE:HAE – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.06. The company had revenue of $339.38 million during the quarter, compared to analyst estimates of $327.86 million. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.10 earnings per share. Equities research analysts predict that Haemonetics will post 5.28 EPS for the current year.
Hedge Funds Weigh In On Haemonetics
Hedge funds have recently bought and sold shares of the company. Kemnay Advisory Services Inc. purchased a new stake in Haemonetics in the 4th quarter worth approximately $26,000. Leonteq Securities AG bought a new position in Haemonetics in the 4th quarter valued at $30,000. EverSource Wealth Advisors LLC grew its position in shares of Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares in the last quarter. Kestra Advisory Services LLC bought a new position in shares of Haemonetics in the fourth quarter worth $34,000. Finally, Bayforest Capital Ltd bought a new position in shares of Haemonetics in the fourth quarter worth $40,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.
Haemonetics Company Profile
Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.
The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.
Featured Stories
- Five stocks we like better than Haemonetics
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.
